Keywords: valeant, 2nd-qtr, income, stays, constant, usa, pharmaceuticals
Valeant's 2nd-qtr 2007 income stays constant
Article | 13 August 2007
The USA's Valeant Pharmaceuticals' second-quarter 2007 revenues totaled $231.0 million versus $230.4 million in the like, year-ago period, as product sales increased 2% to $212.1 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
